Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI354 in Locally Advanced Unresectable or Metastatic Solid Tumors
NCT05636215Phase 2Recruiting
- Sponsor
- Innovent Biologics
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of IBI354 in solid tumor, sponsored by Innovent Biologics. Primary endpoints: Incidence of serious adverse events, Incidence of treatment-emergent adverse events and 1 more. Started Apr 2023; status: recruiting.
02
Drugs
IBI354
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05636215.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05636215.